Stock Quote
Amgen Inc. (AMGN.O) (Nasdaq)
$55.38
20 Nov 2009
-1.21%
$56.06
$55.79
9,493,251
$55.79
$55.12
$64.76
$44.96
0.52
6,024,566
AMGN.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Sharer, Kevin | Chairman of the Board, President, Chief Executive Officer | 14,512,800 |
| Bradway, Robert | Chief Financial Officer, Executive Vice President | 4,236,080 |
| Bonanni, Fabrizio | Executive Vice President - Operations | 6,268,960 |
Profile
Amgen Inc. is a biotechnology company that discovers, develops, manufactures and markets human therapeutics-based on advances in cellular and molecular biology. The Company operates in human therapeutics. It markets human therapeutic products in the areas of supportive cancer care, nephrology and... Full Description
Company Address
Amgen Inc.
One Amgen Center Drive
Thousand Oaks CA 91320
P: +1805.4471000
F: +1805.4471010
One Amgen Center Drive
Thousand Oaks CA 91320
P: +1805.4471000
F: +1805.4471010
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Johnson & Johnson | $62.31 | +0.37 |
| Roche Holding Ltd. | CHF162.70 | +1.60 |
| Roche Holding Ltd. | CHF167.30 | +1.80 |
| AMGN.O | Industry | |
|---|---|---|
| P/E(TTM) | 12.33 | 12.80 |
| P/S(TTM) | 3.84 | 29.90 |
| ROI(TTM) | 13.62 | 2.35 |
| ROE(TTM) | 21.71 | 3.59 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 1.20 |
| EPS Est. (Current Year) | 5.05 |
| Total Revenue | $3,812.00M |
| Net Income | $1,386.00M |
| EPS | $1.36 |
